Assist Devices Fail to Reverse Patterns of Fetal Gene Expression Despite β-Blockers

Journal of Heart and Lung Transplantation

Volumn 26, Issue 11, 2007, Pages 1170-1176

  Lowes, Brian D ^a   Zolty, Ronald ^a   Shakar, Simon F ^a   Brieke, Andreas ^a   Gray, Norman ^a   Reed, Michael ^a   Calalb, Mihail ^a   Minobe, Wayne ^a   Lindenfeld, JoAnn ^a   Wolfel, Eugene E ^a   Geraci, Mark ^a   Bristow, Michael R ^a   Cleveland Jr , Joseph ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MYOSIN HEAVY CHAIN ALPHA; TROPOMYOSIN;

ADULT; ARTICLE; ASSISTED CIRCULATION; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEVICE; GENE EXPRESSION; HEART LEFT VENTRICLE; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; ORGAN DONOR; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; WESTERN BLOTTING;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GLUCOSE TRANSPORTER TYPE 1; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOSIN HEAVY CHAINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-SERINE-THREONINE KINASES; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TROPOMYOSIN;

EID: 36048938391     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.08.003     Document Type: Article

References (50)

1. Rose E.A., Gelijns A.C., Moskowitz A.J., et al., The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
2. Long J.W., Kfoury A.G., Slaughter M.S., et al. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. Congest Heart Fail 11 (2005) 133-138
3. Nakatani S., McCarthy P.M., Kottke-Marchant K., et al. Left ventricular echocardiographic and histologic changes: impact of chronic unloading by an implantable ventricular assist device. J Am Coll Cardiol 27 (1996) 894-901
4. Muller J., Wallukat G., Weng Y.G., et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 96 (1997) 542-549
5. Mancini D., Goldsmith R., Levin H., et al. Comparison of exercise performance in patients with chronic severe heart failure versus left ventricular assist devices. Circulation 98 (1998) 1178-1183
6. Dandel M., Weng Y., Siniawski H., Potapov E., Lehmkuhl H.B., and Hetzer R. Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. Circulation 112 9 suppl (2005) I37-I45
7. Mann D.L., and Willerson J.T. Left ventricular assist devices and the failing heart: a bridge to recovery, a permanent assist device, or a bridge too far?. Circulation 98 (1998) 2367-2369
8. Kinoshita M., Takano H., Takaichi S., Taenaka Y., and Nakatani T. Influence of prolonged ventricular assistance on myocardial histopathology in intact heart. Ann Thorac Surg 61 (1996) 640-645
9. Milting H., Jacob M., Kassner A., et al. The structural examination of myocardial samples from patients with end-stage heart failure supported by ventricular assist devices using electron microscopy and amino acid analysis reveals low degree of reverse remodeling. J Heart Lung Transplant 23 (2004) 396-404
10. Soloff L.A. Atrophy of myocardium and its myocytes by left ventricular assist device. Circulation 100 (1999) 1012
11. Galinanes M., Zhai X., and Hearse D.J. The effect of load on atrophy, myosin isoform shifts and contractile function: studies in a novel rat heart transplant preparation. J Mol Cell Cardiol 27 (1995) 407-417
12. Parker T.G., Packer S.E., and Schneider M.D. Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest 85 (1990) 507-514
13. Razeghi P., Young M.E., Alcorn J.L., Moravec C.S., Frazier O.H., and Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 104 (2001) 2923-2931
14. Lowes B.D., Minobe W., Abraham W.T., et al. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 100 (1997) 2315-2324
15. Haddad F., Bodell P.W., and Baldwin K.M. Pressure-induced regulation of myosin expression in rodent heart. J App Physiol 78 (1995) 1489-1495
16. Swynghedauw B. Remodeling of the heart in chronic pressure overload. Basic Res Cardiol 86 suppl 1 (1991) 99-105
17. Kinugawa K., Minobe W.A., Wood W.M., et al. Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation 103 (2001) 1089-1094
18. Klein I., and Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 344 (2001) 501-509
19. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91 (2002) 988-998
20. Razeghi P., Essop M.F., Huss J.M., Abbasi S., Manga N., and Taegtmeyer H. Hypoxia-induced switches of myosin heavy chain iso-gene expression in rat heart. Bioche Biophys Res Commun 303 (2003) 1024-1027
21. Rundell V.L., Geenen D.L., Buttrick P.M., and de Tombe P.P. Depressed cardiac tension cost in experimental diabetes is due to altered myosin heavy chain isoform expression. Am J Physiol Heart Circ Physiol 287 (2004) H4-H13
22. Waspe L.E., Ordahl C.P., and Simpson P.C. The cardiac beta-myosin heavy chain isogene is induced selectively in alpha 1-adrenergic receptor-stimulated hypertrophy of cultured rat heart myocytes. J Clin Invest 85 (1990) 1206-1214
23. Lowes B.D., Gill E.A., Abraham W.T., et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 83 (1999) 1201-1205
24. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
25. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure MERIT-HF Study Group. JAMA 283 (2000) 1295-1302
26. Lowes B.D., Zolty R., Minobe W.A., et al. Serial gene expression profiling in the intact human heart. J Heart Lung Transplant 25 (2006) 579-588
27. Lowes B.D., Gilbert E.M., Abraham W.T., et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346 (2002) 1357-1365
28. Carniel E., Taylor M.R., Sinagra G., et al. Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy. Circulation 112 (2005) 54-59
29. Razeghi P., Young M.E., Ying J., et al. Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology 97 (2002) 2-9
30. de Brouwer K.F., Degens H., Aartsen W.M., et al. Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice. J Mol Cell Cardiol 40 (2006) 838-4
31. Lopez-Lazaro M. HIF-1: hypoxia-inducible factor or dysoxia-inducible factor?. FASEB J 20 (2006) 828-832
32. Wykoff C.C., Pugh C.W., Maxwell P.H., Harris A.L., and Ratcliffe P.J. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19 (2000) 6297-6305
33. Shyu K.G., Liou J.Y., Wang B.W., Fang W.J., and Chang H. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. J Biomed Sci 12 (2005) 409-420
34. Minet E., Mottet D., Michel G., et al. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett 460 (1999) 251-256
35. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., and Neckers L.M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277 (2002) 29936-29944
36. Ebert B.L., Firth J.D., and Ratcliffe P.J. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 270 (1995) 29083-29089
37. Hagele S., Behnam B., Borter E., et al. TSGA10 prevents nuclear localization of the hypoxia-inducible factor (HIF)-1alpha. FEBS Lett 580 (2006) 3731-3738
38. Tan F.L., Moravec C.S., Li J., et al. The gene expression fingerprint of human heart failure. Proc Natl Acad Sci U S A 99 (2002) 11387-11392
39. Barrans J.D., Allen P.D., Stamatiou D., Dzau V.J., and Liew C.C. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 160 (2002) 2035-2043
40. Yang J., Moravec C.S., Sussman M.A., et al. Decreased SLIM1 expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation 102 (2000) 3046-3052
41. Blaxall B.C., Tschannen-Moran B.M., Milano C.A., and Koch W.J. Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol 41 (2003) 1096-1106
42. Wohlschlaeger J., Schmitz K.J., Schmid C., et al. Reverse remodeling following insertion of left ventricular assist devices (LVAD): a review of the morphological and molecular changes. Cardiovasc Res 68 (2005) 376-386
43. Burkhoff D., Klotz S., and Mancini D.M. LVAD-induced reverse remodeling: basic and clinical implications for myocardial recovery. J Card Fail 12 (2006) 227-239
44. Heerdt P.M., Holmes J.W., Cai B., et al. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 102 (2000) 2713-2719
45. Noguchi T., Hunlich M., Camp P.C., et al. Thin-filament-based modulation of contractile performance in human heart failure. Circulation 110 (2004) 982-987
46. Bristow M.R., Krause-Steinrauf H., Nuzzo R., et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 10 (2004) 1437-1442
47. Swedberg K., Bristow M.R., Cohn J.N., et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105 (2002) 1797-1803
48. Tevaearai H.T., Eckhart A.D., Walton G.B., et al. Myocardial gene transfer and overexpression of beta2-adrenergic receptors potentiates the functional recovery of unloaded failing hearts. Circulation 106 (2002) 124-129
49. Ahmet I., Lakatta E.G., and Talan M.I. Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1 AR blockade in rodent dilated ischemic cardiomyopathy. Heart Fail Rev 10 (2005) 289-296
50. Birks E.J., Tansley P.D., Hardy J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 355 (2006) 18-84